Occident Research
Investment Thesis
OCCIDENT is an owner-operated Venture Capital investor headquartered in Munich, Germany, with roots in Switzerland dating back to 2012. The firm's tagline, "The Science Investor," captures its core thesis: it finances spin-offs out of scientific research that translate breakthrough discoveries into concrete products with measurable societal benefit. OCCIDENT invests its own capital (owner-managed, not a traditional LP-funded fund structure) and frames every decision around long-term, sustainable success potential rather than short-cycle returns. The firm explicitly positions itself as a long-term partner to its portfolio companies, offering not just capital but deep technical understanding, an entrepreneurial mindset, and hands-on support through to exit.
Sector Focus
OCCIDENT organizes its portfolio into three categories:
- Lifesciences — the clear center of gravity, spanning biotech (antibody-drug conjugates, gene therapy, small-molecule pharma), medtech (implantable devices, diagnostics, protontherapy-adjacent devices), and digital health/diagnostics tooling
- Industrial Tech — deep-tech hardware and materials science, including semiconductor test chips, catalysts for fuel cells/electrolyzers, and embedded sensor technology for machinery
- Digital — a smaller, largely legacy bucket from the firm's earlier years (music-rights technology, enterprise software)
The current investment focus is overwhelmingly Lifesciences, with Industrial Tech as a secondary but active theme (the firm made its first Industrial Tech investment in 2022).
Stage Focus
OCCIDENT has historically described itself as investing "from the Seed round onward," but recent activity shows direct participation as early as Pre-Seed (Immitra Bio, July 2026) through to late-stage growth rounds (Tubulis Series C, October 2025, more than €300M raised). In practice the firm spans Pre-Seed through Series C, with Seed and Series A as the most common entry points for new relationships and continued follow-on support into later rounds for existing portfolio companies.
Check Size
OCCIDENT does not publish a specific check-size range on its website. Given its small team (4 people) and history of co-investing alongside larger healthcare-focused funds (e.g., Venrock Healthcare Capital Partners led the Tubulis Series C), it likely writes smaller checks relative to round size and follows rather than sets round economics at later stages, while playing a more central role in early rounds tied to its university spin-off origination.
Lead Tendency
Public disclosures consistently use "beteiligt sich an" (participates in) rather than language indicating OCCIDENT leads rounds, including for both the Immitra Bio Pre-Seed round and the Tubulis Series C. Lead tendency is therefore assessed as unknown/likely follower at growth stage, though the firm may take a more central sourcing role at first institutional check given its origin as direct financier of university spin-offs.
Recent Activity
OCCIDENT has been active and well-covered in its news feed (11 pages of news items, sampled from the first page):
- July 2026: Invested in Immitra Bio's CHF 2.4M Pre-Seed round (ETH Zürich spin-off developing in-vivo gene therapy for rare genetic diseases)
- April 2026: Portfolio company Tubulis announced a definitive acquisition agreement with Gilead — a standout exit
- October 2025: Tubulis raised a Series C of over €300M, led by Venrock Healthcare Capital Partners, to advance antibody-drug conjugate (ADC) development
- June 2025: Thermosome reported promising Phase 1 data for its lead tumor-targeting compound THE001
- June 2025: ReCatalyst (fuel-cell catalyst spin-off) established a strong advisory board
- February 2025: Algiax Pharmaceuticals presented promising Phase 2 results for AP-325 in neuropathic pain
- January 2025: Tubulis advanced its second drug candidate (TUB-030) into clinical evaluation
Fund status reads as actively deploying, with the firm noting on its site that its portfolio grew past 25 startups and 5 exits by 2023, and currently reports 14 active portfolio companies and 7 successful exits.
Portfolio Highlights
Notable exits:
- Tubulis — antibody-drug conjugate (ADC) developer; acquisition agreement with Gilead announced April 2026 following a >€300M Series C in October 2025
- adivo — acquired by Zoetis (animal health), announced September 2023
- Cunesoft — exited January 2020
- Kooaba — image-recognition startup acquired by Qualcomm, January 2014
Active portfolio highlights (Lifesciences-heavy): Immitra Bio (gene therapy), Lymphatica Medtech (implantable lymphedema device), Altavo (AI/radar-based artificial voice for laryngectomy patients), EBAMed (protontherapy-adjacent cardiac radioablation), Avelo (breath-based tuberculosis diagnostics), hemotune (magnetic blood purification), Algiax Pharmaceuticals (neuropathic pain), Thermosome (targeted tumor therapy), Resistell (phenotypic antibiotic-resistance testing), G-Metrics (digital glaucoma management), InSphero (3D cell culture models), Lunaphore, Versantis, and GNA Biosolutions. Industrial Tech highlights include Chipmetrics (semiconductor test chips), ReCatalyst (fuel-cell catalysts), and core sensing (embedded machinery sensors).
Team
- Patrizia Schützenhöfer, Chief Executive Officer (CEO) — leads OCCIDENT and sets corporate strategy; carries all investment decisions; also responsible for Finance, HR, and Marketing. Background in business studies in Vienna, international corporate marketing (internet, consumer goods), and long-standing experience as a real estate and venture capital investor.
- Michael Pauer, Chief Investment Officer (CIO) — leads Investment Management, shepherds every investment case through closing, defines deal terms, and drives portfolio management; carries all investment decisions and oversees Controlling. Background in business studies in Vienna, controlling roles at international food and telecom corporates, and long-standing experience as a venture capital investor.
- Cédric Barra, Senior Investment Manager — leads the Lifesciences team; responsible for deal sourcing, due diligence, and active portfolio management in Lifesciences. Background in pharmacy and business studies in Zurich, with long experience in private equity and venture capital.
- Paul Sunzenauer (Paul Stephan Sunzenauer), Junior Investment Manager — focused on disruptive Lifesciences and biotech innovation; responsible for deal sourcing, due diligence, and portfolio building. Master's in Management from TU Munich and chemistry studies in Linz; prior experience as an innovation consultant and in fintech-startup management.
Decision Process
Small partnership structure: both the CEO and CIO are described as carrying "all investment decisions," consistent with a tight, owner-led partnership rather than a formal investment committee. Total headcount is 4.
Founder Preferences
OCCIDENT's origin story and stated values ("Innovation," "Sinnhaftigkeit" [purpose], "Expertise," "Partnerschaft," "Integrität") indicate a strong preference for scientific/technical founding teams emerging directly from university or research-institute spin-offs (ETH Zürich, National Institute of Chemistry Ljubljana, and similar), where deep domain expertise and a clear societal-impact angle are present.
Geographic Focus
Primarily DACH and broader continental Europe: headquartered in Munich, Germany (Ludwigstraße 8, 80539 München), with origins in Switzerland (2012) and a portfolio spanning Germany, Switzerland, Austria, Finland (Chipmetrics), and Slovenia (ReCatalyst).
Firm History
Founded in 2012 in Switzerland by Patrizia Schützenhöfer and Michael Pauer out of a shared fascination with innovative technology and breakthrough scientific research. Key milestones: first Investment Manager and Lifesciences focus plus first exit (2014); first VC investment in Germany (2016); portfolio passes 10 startups (2018); second location opened in Munich (2019); first Industrial Tech Investment Manager hired (2020); Munich becomes new headquarters (2021); first Industrial Tech investment made (2022); portfolio passes 25 startups and 5 exits (2023).